These results indicate that gliomas with active RTK/Ras/PI3K/AKT signaling are responsive to ICI immunotherapy via the targeting of PD-1/PD-L1 both on tumor cells and tumor-associated macrophages. This evidence concerns the gene AKT1 and central nervous system cancer.